Condition
Malignant Pleural Mesothelioma
Estimated Enrollment: 344
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment
Study ID Numbers: VS-6063-202
Study First Received: May 29, 2013
Last Updated: January 26, 2017
Estimated Primary Completion Date: January 2016
Primary Outcome Measures:
Compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo|Compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving defactinib (VS-6063) or placebo|To assess Quality of Life (QoL) in subjects treated with defactinib (VS-6063) or placebo using the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|To determine the objective response rate (ORR) in subjects receiving defactinib (VS-6063) or placebo.
Sponsors and Collaborators:
Verastem, Inc.
Website Link: https://ClinicalTrials.gov/show/NCT01870609
